These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 37553698)

  • 1. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
    Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
    Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
    Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
    Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
    Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
    Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
    Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
    Liu Z; Sun L; Peng X; Liu S; Zhu Z; Huang C
    Apoptosis; 2023 Dec; 28(11-12):1564-1583. PubMed ID: 37580435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma.
    Zhou X; Xu R; Lu T; Wang C; Chang X; Peng B; Shen Z; Yao L; Wang K; Xu C; Shi J; Zhang R; Zhao J; Zhang L
    Sci Rep; 2023 Aug; 13(1):13305. PubMed ID: 37587188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
    Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
    Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
    Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
    Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
    Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
    Front Immunol; 2022; 13():749241. PubMed ID: 35529878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel immunogenic death-associated model for predicting the immune microenvironment in lung adenocarcinoma from single-cell and Bulk transcriptomes.
    Pan X; Chen H; Zhang L; Xie Y; Zhang K; Lian C; Wang X
    J Cancer; 2024; 15(16):5165-5182. PubMed ID: 39247599
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
    Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
    Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma.
    Peng L; Xu S; Xu JL
    J Hepatocell Carcinoma; 2024; 11():879-900. PubMed ID: 38770169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
    Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an immunogenic cell death prognostic signature for predicting clinical outcome and immune infiltration characterization in stomach adenocarcinoma.
    Liu Y; Zhang L; Lei X; Yin X; Liu S
    Aging (Albany NY); 2023 Oct; 15(20):11389-11411. PubMed ID: 37862109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and comprehensive analysis of a novel prognostic signature associated with immunogenic cell death molecular subtypes in patients with bladder cancer.
    Gu L; Hu G; Hu J; Wen F
    Heliyon; 2023 Aug; 9(8):e18848. PubMed ID: 37593621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.